Mace

(redirected from Major Adverse Cardiovascular Events)
Also found in: Dictionary, Thesaurus, Financial, Encyclopedia.

Mace

 [mās]
trademark for an aerosol mixture of CS, a common tear gas.

Mace

, MACE (mās),
Acronym for methylchloroform 2-chloracetophenone (the prototypical lacrimator) in a light petroleum dispersant and a pressurized propellant.

mace

[mās]
the oil-containing, red, fibrous wrapping of the nutmeg kernel. Dried and ground, it is used as an aromatic spice and flavoring. Historical medicinal uses include the treatment of gastrointestinal disorders and as an analgesic; however, there are no clinical trials supporting its effectiveness. Compare Mace.

Mace

a trademark for a chemical agent that causes tearing and eye pain. The name is an abbreviation formed by letters in methylchloroform-2-chloroacetophenone, which is dispersed from a pressurized container to immobilize an attacker.
An acronym for objective measures of acute and/or adverse cardiovascular events (e.g., acute myocardial infarction, ischaemic stroke, coronary arterial occlusion, death) which are used to assess the effects of various interventions (e.g., rotablation, angioplasty, stenting) or therapeutics (e.g., antiarrhythmics, statins, ACE inhibitors) on outcomes, in the context of a clinical trial.

Mace

A tear gas made from the lacrimatory agent chloracetophenone combined with a dispersant and an aerosol propellant.
References in periodicals archive ?
A formal cost-benefit analysis wasn't done in SES-SMART, but the lower rates of restenosis and major adverse cardiovascular events leave no doubt that drug-eluting stents, despite their higher acquistion cost, are cost-effective in small coronary arteries, Dr.
The primary endpoint of the VISTA-16 study is a composite of the time to occurrence of a secondary major adverse cardiovascular event consisting of unstable angina requiring urgent hospitalization, myocardial infarction, stroke and cardiovascular death.
The primary safety objective is to evaluate the incidence of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction or stroke.
BETonMACE will assess the effect of apabetalone (RVX-208) on time to first occurrence of Major Adverse Cardiovascular Events (MACE) in high-risk type 2 DM patients with CAD.
Under the 2014 guidelines, it's also important to incorporate the surgical risk with an estimate of the individual's personalized risk of perioperative major adverse cardiovascular events.
The rate of major adverse cardiovascular events was higher among patients treated with varenicline than those on placebo in a meta-analysis, but the difference was not statistically significant, according to the latest Food and Drug Administration statement on the cardiovascular safety of the smoking cessation drug.
Compared with noncarriers, the risk for developing major adverse cardiovascular events is 1.
The article is entitled South Asian Ethnicity as a Risk Factor for Major Adverse Cardiovascular Events After Renal Transplantation.
Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease.
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
com) is a randomized, double-blind, placebo-controlled cardiovascular outcomes trial evaluating the occurrence of major adverse cardiovascular events (MACE) in patients participating in the study.

Full browser ?